Background: Lichen striatus (LS) is a benign, mostly self-limiting dermatological condition, primarily affecting the skin, and sometimes the nails. It is characterised by the sudden onset of a band-like rash, typically following Blaschko lines. The exact cause of LS is not well established, but it is believed to be an abnormal immune response to the altered keratinocyte clone after a triggering event.
View Article and Find Full Text PDFIntroduction: The natural history, the progression of a disease process in an individual over time, has not yet been fully elucidated in hidradenitis suppurativa (HS). In this large multicenter study, we aimed to investigate the natural history of HS and its gender differences.
Methods: This cross sectional study included 827 patients.
In this investigation, a novel environmentally friendly functionalized fluorescent Sp-TAB hybrid material was advanced for the sensitive detection of environmentally polluting Hg(II). The characterization of the synthesized fluorescent Sp-TAB hybrid material using SEM and EDX provided insights into morphological and structural changes in the material's pore structure, while XRD and FT-IR analyses revealed the impact of the prepared material at each stage. Optimal parameters such as temperature, contact time, and pH influencing Hg(II) ion detection were determined.
View Article and Find Full Text PDFPollution from heavy metal ions has become a major issue worldwide. Water pollution, particularly with heavy metals like mercury, is a global problem. Developing environmentally friendly, low-cost, high-efficiency, sensitive, and selective sensors for the detection of mercury(ii) ions in aqueous environments has attracted great interest in industry and academia.
View Article and Find Full Text PDFObjectives: To determine the efficacy and safety of brolucizumab therapy administered on a (PRN) basis without loading dose in treatment naïve patients with diabetic macular edema (DME) for 1 year follow-up.
Methods: Patients with recent DME (<6 months) received a mandatory brolucizumab injection at inclusion and other injections could be given on a PRN basis with an 8-week interval (between injections) at minimum. Rescue therapy with other anti-VEGF was possible in case of incomplete DME resolution after the second brolucizumab with a minimum of 1-month treatment free interval between 2 injections.